Review: nanoparticle delivery of calorie-restriction mimetics for brain aging
This review describes nanoparticle carriers as a proposed way to improve delivery of calorie-restriction mimetics such as metformin, spermidine and curcumin to the brain, and discusses challenges for clinical translation in age-associated neurodegeneration. [1]
Automatic summary · not editorially reviewed
The key findings
Caloric restriction has shown neuroprotective effects, but its long-term effects in humans remain challenging. [1]
Clinical translation of calorie-restriction mimetics is limited by poor bioavailability, rapid metabolism, low aqueous solubility and inefficient blood-brain barrier penetration. [1]
The review highlights CRM-loaded nanocarriers as emerging therapeutic systems proposed to delay brain aging and age-associated disorders. [1]
The source at a glance
- Study type / format
- Review abstract
- Population / context
- Brain aging and age-associated neurodegenerative disorders, discussed in a review of calorie-restriction mimetics and nanocarrier delivery
- Summary based on
- Study abstract
- Original publication
- June 8, 2026
Calorie-restriction mimetics and their delivery limits
Brain aging is linked mainly to declining cognitive function and is described as a major risk factor for neurodegenerative disorders. Caloric restriction has shown neuroprotective effects, but long-term use in humans is described as challenging. Calorie-restriction mimetics such as metformin, spermidine and curcumin are used because they can reproduce key molecular effects of caloric restriction. Their clinical translation is described as limited by poor bioavailability, rapid metabolism, low water solubility and inefficient passage across the blood-brain barrier.
Supporting source [1]
Proposed nanocarriers for brain-targeted delivery
The review presents nanoparticle-based drug delivery as a promising approach to these limits. Polymeric, liposomal and lipid-based nanocarriers can, according to the review, be designed to increase transport across the blood-brain barrier via receptor-mediated transcytosis and to allow targeted, sustained drug release. Encapsulating calorie-restriction mimetics in nanoparticles is described as improving their pharmacokinetic and pharmacodynamic profiles by increasing stability and bioavailability and reducing systemic degradation. The review states that targeted delivery of these mimetics has been shown to modulate aging-associated pathways needed to maintain neuronal integrity and synaptic function.
Supporting source [1]
Review scope: proposed systems, not proven clinical benefit
The source is an abstract of a review, not a new study. It highlights CRM-loaded nanocarriers as emerging therapeutic systems proposed to delay brain aging and age-associated disorders, and it discusses current challenges and future perspectives on optimizing brain-targeted delivery for successful clinical translation in age-related neurodegenerative disorders. The abstract reports no human trial results, no tested clinical outcomes and no evidence that these carriers prevent or treat disease.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. It reports no primary study design, sample, follow-up or measured outcomes, and the nanocarrier approach is presented as proposed, not as a validated or clinically proven therapy.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Prabhu P, Pai V, Singh AK. · europepmc.org · June 8, 2026